MARC details
000 -LEADER |
fixed length control field |
02784nam a22003737a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
170823s20172017 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
2049-3614 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
28790138 |
245 ## - TITLE STATEMENT |
Title |
Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models. |
251 ## - Source |
Source |
Endocrine Connections. , 2017 Aug 08 |
252 ## - Abbreviated Source |
Abbreviated source |
Endocr. connect.. , 2017 Aug 08 |
252 ## - Abbreviated Source |
Former abbreviated source |
Replace Dates |
253 ## - Journal Name |
Journal name |
Endocrine connections |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2017 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2018 |
266 ## - Date added to catalog |
Date added to catalog |
2017-08-23 |
520 ## - SUMMARY, ETC. |
Abstract |
BACKGROUND: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells. |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSIONS: Our data show that amifostine has no protective effect on thyroid cancer cells against DNA damaging agents in vitro and suggest that amifostine will not attenuate the efficacy of radioiodine treatment in patients with thyroid cancer. |
520 ## - SUMMARY, ETC. |
Abstract |
METHODS: We investigated the effects of the active form of amifostine (WR-1065) on the response of thyroid cancer cells to treatment with DNA damaging agents. WR-1065 was examined in human thyroid cancer cell lines (FTC133, TPC1, BCPAP and C643) and embryonic fibroblast cells NIH3T3. DNA damage was induced by exposure to H2O2 (0.1 mM), by treatment with the radiomimetic neocarzinostatin (NCS 250 ng/ml), and by gamma -radiation (6Gy). DNA damage, cell viability and apoptosis were examined. |
520 ## - SUMMARY, ETC. |
Abstract |
RESULTS: We demonstrated selective action of WR-1065 (0.1mM), which prevented oxidative stress induced DNA damage in fibroblasts, but did not protect thyroid cancer cells from DNA damage and apoptosis documented by caspase-3 and PARP cleavage after exposure to H2O2, NCS, and gamma-radiation. Prolonged exposure to WR-1065 (0.1 mM for 24 hours) was toxic for thyroid cancer cells; this treatment decreased the number of viable cells by 8% in C643 cells, 47% in TPC cells, 92% in BCPAP cells, and 82% in FTC 133 cells. The cytotoxic effects of WR-1065 were not associated with induction of apoptosis. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
PubMed-not-MEDLINE -- Not indexed |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Endocrinology |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Nuclear Medicine |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Burman, Kenneth D |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Van Nostrand, Douglas |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Wartofsky, Leonard |
790 ## - Authors |
All authors |
Burman K, Costello J, Jensen K, Klubo-Gwiezdzinska J, Patel A, Tkavc R, Van Nostrand D, Vasko V, Wartofsky L |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1530/EC-17-0138">https://dx.doi.org/10.1530/EC-17-0138</a> |
Public note |
https://dx.doi.org/10.1530/EC-17-0138 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |